ESMO21: Libtayo extends survival in first-line NSCLC, challenging KeytrudaThere’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the Share XESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytrudahttps://pharmaphorum.com/news/esmo21-libtayo-extends-survival-in-first-line-nsclc-challenging-keytruda/
Sanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancerSanofi and Regeneron’s latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche Share XSanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancerhttps://pharmaphorum.com/news/sanofi-regeneron-eye-libtayo-challenge-to-merck-in-first-line-lung-cancer/
Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
Sanofi, Regeneron prep filings for Libtayo in cervical cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a Share XSanofi, Regeneron prep filings for Libtayo in cervical cancerhttps://pharmaphorum.com/news/sanofi-regeneron-prep-filings-for-libtayo-in-cervical-cancer/
Sanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancerSanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated Share XSanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancerhttps://pharmaphorum.com/news/sanofis-immunotherapy-libtayo-gets-fda-not-in-first-line-lung-cancer/
Regeneron pairs with BioNTech on melanoma immunotherapyRegeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech Share XRegeneron pairs with BioNTech on melanoma immunotherapyhttps://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/
Regeneron gets closer to ISA Pharma with new immuno-oncology allianceRegeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch Share XRegeneron gets closer to ISA Pharma with new immuno-oncology alliancehttps://pharmaphorum.com/news/regeneron-gets-closer-to-isa-pharma-with-new-immuno-oncology-alliance/
